The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

AIM: Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Main Authors: Bachmann, Hagen Sjard, Meier, Werner, du Bois, Andreas, Kimmig, Rainer, Kuhlmann, Jan Dominik, Siffert, Winfried, Sehouli, Jalid, Wollschlaeger, Kerstin, Huober, Jens, Hillemanns, Peter, Burges, Alexander, Schmalfeldt, Barbara, Aminossadati, Behnaz, Wimberger, Pauline
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Ltd 2015
Assuntos:
Pharmacogenetics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631186/
https://ncbi.nlm.nih.gov/pubmed/26033044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12688
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares